Response estimates by protocol and GEP-70 risk. Cumulative incidence of CR (CRI) and CRD are analyzed according to plasma cell GEP-based low- and high-risk subsets. Common to all endpoints examined, plateaus are reached earlier in high-risk (B: CRI, D: CRD) than patients with low-risk myeloma (A: CRI, C: CRD). (A) Cumulative incidence of CR: GEP-70 low-risk only. (B) Cumulative incidence of CR: GEP-70 high-risk only. (C) CRD by protocol: GEP-70 low-risk only. (D) CRD by protocol: GEP-70 high-risk only.